| NCT ID | NCT01587300 |
| Status | Recruiting |
| Phase | — |
| Sponsor | New Approaches to Neuroblastoma Therapy Consortium |
| Condition | Neuroblastoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2011-07 |
| Primary Completion | 2099-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2011-07 with a primary completion date of 2099-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.
Eligibility Criteria
Inclusion Criteria: * Patients must be greater than or 31 days of age. * Patients must have had a diagnosis of high risk neuroblastoma either by histological verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines. * All patients with refractory or recurrent high risk neuroblastoma at NANT institutions are eligible regardless of disease status (including no measurable or evaluable tumor) as long as they undergo a disease evaluation and appropriate samples are submitted. * Additionally, all patients with high risk neuroblastoma without relapse treated at a NANT institution are eligible if undergoing a disease evaluation, as long as Children's Oncology Group specimens are prioritized. Exclusion Criteria: * There are no exclusion criteria on this study.
Contact & Investigator
Shahab Asgharzadeh, MD
STUDY CHAIR
Children's Hospital Los Angeles
Frequently Asked Questions
Who can join the NCT01587300 clinical trial?
This trial is open to participants of all sexes, aged 31 Days or older, up to 99 Years, studying Neuroblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01587300 currently recruiting?
Yes, NCT01587300 is actively recruiting participants. Contact the research team at amarachelian@chla.usc.edu for enrollment information.
Where is the NCT01587300 trial being conducted?
This trial is being conducted at Los Angeles, United States, Palo Alto, United States, San Francisco, United States, Aurora, United States and 11 additional locations.
Who is sponsoring the NCT01587300 clinical trial?
NCT01587300 is sponsored by New Approaches to Neuroblastoma Therapy Consortium. The principal investigator is Shahab Asgharzadeh, MD at Children's Hospital Los Angeles. The trial plans to enroll 1,000 participants.